REGN: Regeneron Pharmaceuticals Inc. Stocks News on October 16, 2025

REGN

MT Newswires

12 hours ago

Rothschild & Co Redburn Adjusts Regeneron Pharmaceuticals Price Target to $900 From $890, Maintains Buy Rating

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

REGN

GlobeNewswire

14 hours ago

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

Regeneron’s Q3 2025 Earnings: What to Expect

REGN

Barchart

a day ago

Regeneron’s Q3 2025 Earnings: What to Expect

2 Stocks Down 17% and 21% to Buy Right Now

REGN

Motley Fool

a day ago

2 Stocks Down 17% and 21% to Buy Right Now

REGN

Zacks

2 days ago

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss

REGN

Insider Monkey

2 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge

Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage)

REGN

Investor's Business Daily

2 days ago

Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage)

REGN

MT Newswires

3 days ago

Regeneron Says Investigational Hearing Loss Therapy Shows Improvement in Almost All Study Participants

How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise?

REGN

Simply Wall St.

3 days ago

How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise?

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

REGN

GlobeNewswire

3 days ago

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

REGN

BioPharma Dive

4 days ago

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

REGN

Investor's Business Daily

6 days ago

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo

REGN

Zacks

6 days ago

Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo

Regeneron, needing a turnaround, gains new use for cancer drug

REGN

BioPharma Dive

7 days ago

Regeneron, needing a turnaround, gains new use for cancer drug

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

REGN

GlobeNewswire

7 days ago

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

REGN

MT Newswires

7 days ago

Regeneron Says FDA Approved Libtayo as Immunotherapy for Adjuvant Treatment of High Risk Skin Cancer

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

REGN

GlobeNewswire

7 days ago

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

REGN

MT Newswires

8 days ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $704 From $695, Keeps Sector Perform Rating

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

REGN

GlobeNewswire

8 days ago

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

11 Cheap Stocks for a Market That’s Too Expensive

REGN

Barrons.com

8 days ago

11 Cheap Stocks for a Market That’s Too Expensive

REGN

Simply Wall St.

8 days ago

Regeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric Approval

REGN

The Wall Street Journal

9 days ago

Health Care Roundup: Market Talk

REGN

MT Newswires

9 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

REGN

MT Newswires

9 days ago

Sector Update: Health Care

REGN

MT Newswires

9 days ago

Regeneron Shares Drop After $83 Million Charge Projected to Reduce Q3 EPS

Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035

REGN

GlobeNewswire

9 days ago

Bullous Pemphigoid Market Analysis and Forecast Report 2025-2035

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

REGN

Zacks

9 days ago

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

REGN

Insider Monkey

13 days ago

Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management

REGN

Argus Research

13 days ago

Analyst Report: Regeneron Phars, Inc

REGN

Argus Research

13 days ago

Market Update: PAYX, REGN

REGN

Simply Wall St.

13 days ago

Does FDA Approval Expansion and Pipeline Progress Change the Bull Case for Regeneron (REGN)?

REGN

Zacks Small Cap Research

13 days ago

LEXX: Biodistribution Study Results

Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline

REGN

Insider Monkey

13 days ago

Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline

REGN

Insider Monkey

13 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough

REGN

Insider Monkey

14 days ago

Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials

REGN

MT Newswires

14 days ago

US Equity Indexes Rise as Healthcare Jumps, October Rate-Cut Certainty Increases Amid Surprise Fall in Private Payrolls

REGN

MT Newswires

14 days ago

Healthcare Helps Lift US Equity Indexes After Federal Shutdown Begins

REGN

MT Newswires

14 days ago

US Equity Indexes Mixed Amid Healthcare Gains While Treasury Yields Drop as Partial Shutdown Begins

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

REGN

GlobeNewswire

15 days ago

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5

REGN

Insider Monkey

15 days ago

Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

REGN

GlobeNewswire

15 days ago

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025

2 Beaten-Down Stocks to Buy and Hold for a Decade

REGN

Motley Fool

16 days ago

2 Beaten-Down Stocks to Buy and Hold for a Decade

REGN

Insider Monkey

16 days ago

Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease

REGN

Insider Monkey

16 days ago

Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2

REGN

Zacks

17 days ago

FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza

Regeneron’s Evkeeza gains FDA approval for young HoFH patients

REGN

Pharmaceutical Technology

17 days ago

Regeneron’s Evkeeza gains FDA approval for young HoFH patients

1 Healthcare Stock with Exciting Potential and 2 We Ignore

REGN

StockStory

17 days ago

1 Healthcare Stock with Exciting Potential and 2 We Ignore

REGN

MT Newswires

20 days ago

Regeneron Says Evkeeza Gets FDA Approval for Children as Young as 1-Year Old With Rare Form of High Cholesterol

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

REGN

GlobeNewswire

20 days ago

Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

REGN

StockStory

20 days ago

Why Regeneron (REGN) Shares Are Falling Today

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

REGN

StockStory

21 days ago

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

Regeneron’s Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide

REGN

Insider Monkey

22 days ago

Regeneron’s Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide

REGN

StockStory

22 days ago

Why Regeneron (REGN) Stock Is Down Today

Stock Market Today: Dow Up Ahead Of Powell Speech; Nvidia At Buy Point (Live Coverage)

REGN

Investor's Business Daily

22 days ago

Stock Market Today: Dow Up Ahead Of Powell Speech; Nvidia At Buy Point (Live Coverage)

US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall

REGN

Reuters

23 days ago

US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall

REGN

Zacks

23 days ago

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

Humana initiated, Paycom upgraded: Wall Street's top analyst calls

REGN

The Fly

23 days ago

Humana initiated, Paycom upgraded: Wall Street's top analyst calls

REGN

MT Newswires

24 days ago

Sanofi, Regeneron Say Potential Chronic Spontaneous Urticaria Treatment Recommended for EU Approval

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

REGN

GlobeNewswire

24 days ago

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism

REGN

Simply Wall St.

a month ago

How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism

Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?

REGN

Investor's Business Daily

a month ago

Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

REGN

Zacks

a month ago

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

Arvinas reboots, cuts more staff; Porges joins Lazard

REGN

BioPharma Dive

a month ago

Arvinas reboots, cuts more staff; Porges joins Lazard

Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks

REGN

GlobeNewswire

a month ago

Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks

REGN

StockStory

a month ago

3 Reasons to Sell REGN and 1 Stock to Buy Instead

REGN

MT Newswires

a month ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

REGN

MT Newswires

a month ago

Sector Update: Health Care Stocks Higher in Afternoon Trading

REGN

MT Newswires

a month ago

Regeneron Says Antibody Combo May Preserve Muscle During Weight Loss

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD

REGN

GlobeNewswire

a month ago

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals' Phase 3 Trial of Garetosmab in Fibrodysplasia Ossificans Progressiva Meets Primary Endpoint

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

REGN

GlobeNewswire

a month ago

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

REGN

Investing.com

a month ago

Kymera initiated at Outperform on potential of lead skin drug

REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial

Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market

REGN

PR Newswire

a month ago

Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market

REGN

Zacks

a month ago

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?

REGN

Insider Monkey

a month ago

BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN)

Does Regeneron Offer Value After Recent Share Price Drop in 2025?

REGN

Simply Wall St.

a month ago

Does Regeneron Offer Value After Recent Share Price Drop in 2025?

REGN

Insider Monkey

a month ago

BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT

Maia’s NSCLC immunotherapy secures Phase II efficacy win

REGN

Clinical Trials Arena

a month ago

Maia’s NSCLC immunotherapy secures Phase II efficacy win

Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market

REGN

Clinical Trials Arena

a month ago

Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

REGN

Zacks

a month ago

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership

REGN

BioPharma Dive

a month ago

Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

REGN

Pharma Voice

a month ago

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy

REGN

Benzinga

a month ago

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy

Regeneron’s cat and birch allergy mAbs score in Phase III trials

REGN

Clinical Trials Arena

a month ago

Regeneron’s cat and birch allergy mAbs score in Phase III trials

REGN

MT Newswires

a month ago

Regeneron Says 5-Year Data Show Libtayo Improved Survival Outcomes in Lung Cancer

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

REGN

GlobeNewswire

a month ago

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer

REGN

The Wall Street Journal

a month ago

Health Care Roundup: Market Talk

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

REGN

Zacks

a month ago

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?

REGN

Zacks

a month ago

Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

REGN

GlobeNewswire

a month ago

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

REGN

Motley Fool

a month ago

2 Beaten-Down Stocks to Buy on the Dip

REGN

Simply Wall St.

a month ago

How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference

REGN

GlobeNewswire

a month ago

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference

REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

REGN

Zacks

a month ago

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'

REGN

Investor's Business Daily

a month ago

Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'

REGN

StockStory

a month ago

Latest Regeneron Pharmaceuticals Inc. (REGN) News on October 16, 2025

Share on Social Networks: